<SEC-DOCUMENT>0001062993-17-000516.txt : 20170206
<SEC-HEADER>0001062993-17-000516.hdr.sgml : 20170206
<ACCEPTANCE-DATETIME>20170206131950
ACCESSION NUMBER:		0001062993-17-000516
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20170131
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170206
DATE AS OF CHANGE:		20170206

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		17574884

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Form 8K - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT><BR></B><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION </FONT><BR>Washington, D.C. 20549
</B></P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>January
31, 2017 </U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.
</FONT></U><BR></B>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><U><B>Nevada </B></U></TD>
    <TD align=center width="33%"><U><B>000-52138 </B></U></TD>
    <TD align=center width="33%"><U><B>20-2000871 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
    <TD align=center width="33%">(IRS Employer </TD></TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=left width="33%">&nbsp; </TD>
    <TD align=center width="33%">Identification No.) </TD></TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><U><B>156 Valleyview Road, Kelowna, BC Canada </B></U></TD>
    <TD align=center width="50%"><U><B>V1X 3M4 </B></U></TD></TR>
  <TR vAlign=top>
    <TD align=center>(Address of principal executive offices) </TD>
    <TD align=center width="50%">(Zip Code) </TD></TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code <B><U>(250)
765-6424 </U></B></P>
<P align=center><B><U>N/A </U><BR></B>(Former name or former address, if changed
since last report.) </P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
<BR>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)<BR>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d
-2(b)) <BR>[&nbsp;&nbsp;&nbsp;&nbsp; ]&nbsp;&nbsp;&nbsp;&nbsp; Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e
-4(c))</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Item 7.01 </B></TD>
    <TD align=left width="90%"><B>Regulation FD Disclosure
</B></TD></TR></TABLE>
<P align=justify>A copy of the news release announcing that Lexaria is being
featured on CEO Clips airing on BNN. CEO Clips profiles is filed as exhibit 99.1
to this current report and is hereby incorporated by reference. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Item 8.01 </B></TD>
    <TD align=left width="90%"><B>Other Events </B></TD></TR></TABLE>
<P align=justify>On January 31, 2017 Lexaria Bioscience Corp. (the &#147;Company&#148; or
&#147;Lexaria&#148;) announced that it is currently being featured on CEO Clips airing on
BNN. CEO Clips profiles some of the most innovative publicly traded companies in
North America and is currently featuring a 15 second clip about Lexaria. </P>
<P align=justify>BTV has
  also produced a CEO clip with Company President John Docherty introducing
  Lexaria&#146;s technology. It has been posted on the Thomson Reuters Insider Network
  where it can be viewed by over 80,000 financial professionals. </P>
<P align=justify>Lexaria has separately engaged SJF Communications for a 3-month
social media campaign designed to distribute Lexaria information to as wide a
network as possible. SJF Communications owns @CanadaPotStocks and is a top influencer with over 18,000
followers on Twitter and is considered a leading source for information &amp;
opportunity in the emerging legal cannabis sector. </P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_2></A>
<P align=center>- 2 - </P>
<P align=justify>&nbsp;</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left ><B>Item 9.01</B> </TD>
    <TD align=left width="90%"><B>Financial Statements and Exhibits</B> </TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee ><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee><a href="exhibit99-1.htm">Press Release dated January 31,
      2017 </a></TD>
  </TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left colSpan=2
    ><I>/s/ Chris Bunka</I> </TD>
    <TD align=left width="49%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left colSpan=2 ><B>Chris Bunka</B> </TD>
    <TD align=left width="49%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left colSpan=2 >CEO, Principal Executive Officer
</TD>
    <TD align=left width="49%" >&nbsp;</TD></TR>
  <TR>
    <TD >&nbsp; </TD>
    <TD width="45%" >&nbsp; </TD>
    <TD width="49%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left >Date: </TD>
    <TD align=left width="45%" >February 6, 2017 </TD>
    <TD align=right width="49%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left ></TD>
    <TD align=left width="45%" >&nbsp; </TD>
    <TD align=left width="49%" >&nbsp;</TD></TR></TABLE><BR>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp.: Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
   <META name="HandheldFriendly" content="true">
</HEAD>

<BODY style="font-size:10pt;">

<HR noshade align="center" width=100% size=3 color="black">
<!--$$/page=--><A name=page_3></A>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B>CEO Clips Features Lexaria on the BNN Channel </B></P>
<P align=justify>Kelowna, BC / January 31, 2017 / Lexaria Bioscience Corp.
(OTCQB:LXRP) (CSE:LXX) (the &#147;Company&#148;) is currently being featured on CEO Clips
airing on BNN. CEO Clips profiles some of the most innovative publicly traded
companies in North America and is currently featuring a 15 second clip about
Lexaria. The clip can also be viewed online via this link: <BR><U>http://www.b-tv.com/lexaria-commercial/</U>
</P>
<P align=justify>BTV has also produced a CEO clip with Company President John
Docherty introducing Lexaria&#146;s technology. The clip can be viewed at
<U>http://www.b-tv.com/lexaria-ceo-clip/</U> and has also been posted on the
Thomson Reuters Insider Network where it can be viewed by over 80,000 financial
professionals at <U>http://reut.rs/2kc0Ewn</U> </P>
<P align=justify>Lexaria has separately engaged SJF Communications for a 3-month
social media campaign designed to distribute Lexaria information to as wide a
network as possible. SJF Communications owns @CanadaPotStocks and is a top
influencer with over 18,000 followers on Twitter and is considered a leading
source for information &amp; opportunity in the emerging legal cannabis sector.
</P>
<P align=justify>Lexaria&#146;s unique patented technology allows for more efficient
and effective absorption of certain molecules such as cannabinoids, while
simultaneously masking and at times even eliminating inherent strong flavours
and/or odors typical of those molecules. Lexaria&#146;s technology is extremely cost
effective to implement and applicable to the widest imaginable spectrum of
foods. </P>
<P align=justify>About Lexaria <BR>Lexaria Bioscience Corp. is a food
biosciences company with a proprietary technology for improved delivery of
bioactive compounds. The Company&#146;s lipophilic enhancement technology has been
shown to enhance the bioavailability of orally ingested cannabinoids, while also
masking taste. This technology promotes healthy ingestion methods, lower overall
dosing and higher effectiveness in active molecule delivery. The Company&#146;s
technology is patent-protected for cannabidiol (CBD) and all other
non-psychoactive cannabinoids, and patent-pending for Tetrahydrocannabinol
(THC), other psychoactive cannabinoids, non-steroidal anti-inflammatory drugs
(NSAIDs), nicotine and other molecules. <U>www.lexariabioscience.com</U> </P>
<P align=justify>About BNN <BR>Business News Network (BNN) is Canada's only all
business specialty channel with real time coverage of global market activity
from a Canadian perspective. </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left>FOR FURTHER INFORMATION PLEASE CONTACT: </TD></TR>
  <TR vAlign=top>
    <TD align=left>Lexaria Bioscience Corp. </TD></TR>
  <TR vAlign=top>
    <TD align=left>Chris Bunka </TD></TR>
  <TR vAlign=top>
    <TD align=left>Chairman &amp; CEO </TD></TR>
  <TR vAlign=top>
    <TD align=left>(250) 765-6424 </TD></TR></TABLE>
<P align=justify>&nbsp;</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<!--$$/page=--><A name=page_4></A>
<P align=justify>FORWARD-LOOKING STATEMENTS <br>
  This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements. Such forward-looking statements are
estimates reflecting the Company's best judgment based upon current information
and involve a number of risks and uncertainties, and there can be no assurance
that other factors will not affect the accuracy of such forward-looking
statements. Access to capital, or lack thereof, is a major risk and there is no
assurance that the Company will be able to raise required working capital.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, the patent application and approval process and other factors which
may be identified from time to time in the Company's public announcements and
filings. There is no assurance that the recent license agreement, hemp oil
sector, or alternative health businesses will provide any benefit to Lexaria, or
that the Company will experience any growth through participation in these
sectors or as a result of the license agreement. There is no assurance that
existing capital is sufficient for the Company's needs or that it will be able
to raise additional capital. There is no assurance that Lexaria will
successfully complete any other contemplated or existing technology license
agreements, nor that Lexaria&#146;s technology will deliver any improvement in taste
or bioavailability with any reliability nor across any product category. There
is no assurance that any planned corporate activity, business venture, or
initiative will be pursued, or if pursued, will be successful. There is no
assurance that any hemp oil or cannabinoid-based product will promote, assist,
or maintain any beneficial human health conditions whatsoever, nor that any
patent application in the USA or any other nation or under any treaty will
result in the award of an actual patent; nor that an award of any actual patent
will protect against challenges from unknown third parties. There is no
assurance that any of Lexaria&#146;s postulated uses, benefits, or advantages for the
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). ViPova<SUP>TM</SUP> products are not intended to diagnose, treat, cure or
prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
